Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Presidential Cancer Panel's Drug Value, Affordability Recommendations Align With Industry Views

Executive Summary

Panel recommends National Academies of Sciences evaluate value frameworks like ICER, identify limitations and strengths and, if necessary, develop a new approach.

You may also be interested in...



Patent “March-In” As Price Control Draw Little Support At US National Academies Meeting

The use of patent “march-in” rights as a tool to control the price of drugs developed with US federal funding support remains substantially less popular with the government-funded research community than with politicians.

Praluent Pricing: Collaboration With ICER Sets A New Standard

Sanofi/Regeneron reveal plans to lower price of PCSK9 blocker Praluent to match ICER's updated recommendation, following assessment based on new outcomes data. Decision sparks debate across industry and raises questions about setting precedent on pricing for the future.

At Cross-Purposes? How Trump Budget's Part D Gap Discount Policy Aligns With New Law

President Trump's 2019 federal budget proposal includes plan to exclude manufacturer discounts in the Medicare Part D coverage gap from beneficiaries' out-of-pocket totals, which may be at odds with recently enacted legislation.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS122704

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel